

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Project of 2005, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
Application Number		09/257,272			
Filing Date		February 25, 1999			
First Named Inventor		Hu, Jing-Shan			
Art Unit		1647			
Examiner Name		Landsman, Robert S.			
Attorney Docket Number		1488.1000009/HCC/LMB			
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
PL	US1	5,776,755	07/07/1998	Alitalo <i>et al.</i>	
	US2	5,932,540	08/03/1999	Hu <i>et al.</i>	
	US3	5,935,820	08/10/1999	Hu <i>et al.</i>	
	US4	6,040,157	03/21/2000	Hu <i>et al.</i>	
	US5	6,130,071	10/10/2000	Alitalo <i>et al.</i>	
	US6	6,221,839	04/24/2001	Alitalo <i>et al.</i>	
	US7	6,245,530	06/12/2001	Alitalo <i>et al.</i>	
	US8	6,403,088	06/11/2002	Alitalo <i>et al.</i>	
	US9	6,645,933	11/11/2003	Alitalo <i>et al.</i>	
✓	US10	2006/0014252 A1	01/19/2006	Lyman, Stewart D.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
PL	FP1	WO 91/02058 A1	02/21/1991	California Biotechnology Inc.	
	FP2	WO 95/24473 A1	09/14/1995	Human Genome Sciences, Inc.	
	FP3	WO 97/00271 A1	01/03/1997	The Regents of the University of California	
	FP4	WO 97/08320 A1	03/06/1997	Morphosys Gesellschaft Für Proteinoptimierung MBH	
	FP5	WO 98/55619 A1	12/10/1998	ASAT AG Applied Science & Technology	Abs
	FP6	WO 99/02545 A2	01/21/1999	Novopharm Biotech Inc.	
	FP7	WO 99/20749 A1	04/29/1999	Medical Research Council	
	FP8	WO 00/73430 A3	12/07/2000	Max-Delbrück-Centrum Für Molekulare Medizin	Abs
✓	FP9	WO 00/75163 A1	12/14/2000	Human Genome Sciences, Inc.	

Examiner Signature		Date Considered	3/30/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	1	of	4	Attorney Docket Number	1488.1000009/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
PL	NPL1	Alderson, R.F., <i>et al.</i> , "Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro," <i>Keystone Symposia, Ocular Cell & Molec. Biol.</i> , pp. 32, Abstract No. 202, Association for Research in Vision and Ophthalmology (February 1999)	
	NPL2	Altshuler, D., <i>et al.</i> , "Taurine promotes the differentiation of a vertebrate retinal cell type in vitro," <i>Development</i> 119:1317-1328, The Company of Biologists Limited (December 1993)	
	NPL3	Better, M., <i>et al.</i> , " <i>Escherichia coli</i> Secretion of an Active Chimeric Antibody Fragment," <i>Science</i> 240:1041-1043, American Association for the Advancement of Science (1988)	
	NPL4	Böcker-Meffert, S., <i>et al.</i> , "Erythropoietin and VEGF Promote Neural Outgrowth from Retinal Explants in Postnatal Rats," <i>Invest. Ophthalmol. Vis. Sci.</i> 43:2021-2026, Association for Research in Vision and Ophthalmology (June 2002)	
	NPL5	Colwell, D.E., <i>et al.</i> , "Method for Generating a High Frequency of Hybridomas Producing Monoclonal IgA Antibodies," <i>Meth. Enzymol.</i> 121:42-51, Academic Press, Inc. (1986)	
	NPL6	Danis, R.P., <i>et al.</i> , "Anti-angiogenic therapy of proliferative diabetic retinopathy," <i>Exp. Opin. Pharma.</i> 2:395-407, Ashley Publications Ltd. (March 2001)	
	NPL7	Enholm, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," <i>Trends Cardiovasc. Med.</i> 8:292-297, Elsevier Science Inc. (October 1998)	
	NPL8	Ferrara, N., "Vascular Endothelial Growth Factor and the Regulation of Angiogenesis," <i>Recent Prog. Hormone Res.</i> 55:15-36, The Endocrine Society (March 2000)	
	NPL9	Gerhardinger, C., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor in the Human Retina and in Nonproliferative Diabetic Retinopathy," <i>Am. J. Pathol.</i> 152:1453-1462, American Society for Investigative Pathology (June 1998)	
✓	NPL10	Halin, C. and Neri, D., "Antibody-Based Targeting of Angiogenesis," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> 18:299-339, Begell House, Inc. (August 2001)	

Examiner Signature		Date Considered	3/30/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/257,272
		Filing Date	February 25, 1999
		First Named Inventor	Hu, Jing-Shan
		Art Unit	1647
		Examiner Name	Landsman, Robert S.
		Attorney Docket Number	1488.1000009/HCC/LMB
Sheet	2	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BZ	NPL11	Hannink, M., <i>et al.</i> , "Deletions in the C-Terminal Coding Region of the v-sis Gene: Dimerization Is Required for Transformation," <i>Molec. Cell. Biol.</i> 6:1304-1314, American Society for Microbiology (1986)	
	NPL12	Hirai, M., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in Postmenopausal Uterine Endometrial Carcinoma," <i>Gynecol. Oncol.</i> 80:181-188, Academic Press (February 2001)	
	NPL13	Houck, K.A., <i>et al.</i> , "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," <i>Molec. Endocrinol.</i> 5:1806-1814, Williams & Wilkins (1991)	
	NPL14	Joosten, V., "The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi," <i>Microbial Cell Factories</i> 2:1-15, BioMed Central (January 2003)	
	NPL15	Kelley, M.W., <i>et al.</i> , "Regulation of Proliferation and Photoreceptor Differentiation in Fetal Human Retinal Cell Cultures," <i>Invest. Ophthalmol. Vis. Sci.</i> 36:1280-1289, Association for Research in Vision and Ophthalmology (June 1995)	
	NPL16	Longo, R., <i>et al.</i> , "Anti-angiogenic therapy: Rationale, challenges and clinical studies," <i>Angiogenesis</i> 5:237-256, Kluwer Academic Publishers (December 2002)	
	NPL17	Ngo, J.T., <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in: <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr., K. and Le Grand, S., eds., Birkhäuser, Boston, MA, pp. 491-495 (January 1994)	
	NPL18	Rudikoff, S., <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> 79:1979-1983, National Academy of Sciences (1982)	
	NPL19	Schlaeppli, J.-M., <i>et al.</i> , "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor," <i>J. Cancer Res. Clin. Oncol.</i> 125:336-342, Springer-Verlag (May 1999)	
✓	NPL20	Schratzberger, P., <i>et al.</i> , "Reversal of experimental diabetic neuropathy by VEGF gene transfer," <i>J. Clin. Invest.</i> 107:1083-1092, American Societies for Clinical Investigation (May 2001)	

Examiner Signature		Date Considered	3/30/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	3	of	4	Attorney Docket Number	1488.1000009/HCC/LMB

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
AL	NPL21	Schulz-Key, S., <i>et al.</i> , "Ciliary Neurotrophic Factor as a Transient Negative Regulator of Rod Development in Rat Retina," <i>Invest. Ophthalmol. Vis. Sci.</i> 43:3099-3108, Association for Research in Vision and Ophthalmology (September 2002)			
	NPL22	Seigel, G.M., "The golden age of retinal cell culture," <i>Molec. Vis.</i> 5:4, Molecular Vision (April 1999)			
	NPL23	Skerra, A. and Plückthun, A., "Assembly of a Functional Immunoglobulin F _v Fragment in <i>Escherichia coli</i> ," <i>Science</i> 240:1038-1041, American Association for the Advancement of Science (1988)			
	NPL24	Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Harwood Academic Publishers (March 1999)			
	NPL25	Vale, P.R., <i>et al.</i> , "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGL1(VEGF2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation Suppl.</i> 100:I-22, Abstract No. 109, American Heart Association Inc. (November 1999)			
	NPL26	Vale, P.R., <i>et al.</i> , "Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis using Left Ventricular Electromechanical Mapping in Patients With Chronic Myocardial Ischemia," <i>Circulation</i> 103:2138-2143, American Heart Association Inc. (May 2001)			
	NPL27	van der Flier, M., <i>et al.</i> , "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis," <i>J. Neuroimmunol.</i> 160:170-177, Elsevier B.V. (March 2005)			
	NPL28	Verma, I.M. and Somia, N., "Gene therapy - promises, problems and prospects," <i>Nature</i> 389:239-242, Macmillan Publishers Ltd. (September 1997)			
	NPL29	Walsh, D.A., "Angiogenesis and arthritis," <i>Rheumatology</i> 38:103-112, British Society for Rheumatology (February 1999)			
✓	NPL30	Winkler, K., <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> 165:4505-4514, The American Association of Immunologists (October 2000)			

Examiner Signature		Date Considered	3/30/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Hu, Jing-Shan
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	4	of	4	Attorney Docket Number	1488.1000009/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
PL	NPL31	Yang, X. and Cepko, C.L., "Flk-1, a Receptor for Vascular Endothelial Growth Factor (VEGF), Is Expressed by Retinal Progenitor Cells," <i>J. Neurosci.</i> 16:6089-6099, Society for Neuroscience (October 1996)	
	NPL32	Yourey, P.A., <i>et al.</i> , "Vascular Endothelial Cell Growth Factors Promote the <i>In Vitro</i> Development of Rat Photoreceptor Cells," <i>J. Neurosci.</i> 20:6781-6788, Society for Neuroscience (September 2000)	
	NPL33	Yourey, P.A., <i>et al.</i> , "Vascular Endothelial Cell Growth Factors Promote the <i>In Vitro</i> Development of Rat Photoreceptor Cells," <i>Molec. Biol. Cell.</i> 10:39a, Abstract No. 227, American Society for Microbiology (November 1999) and 39 th Ann. Meeting of the American Society of Cell Biology, Washington, DC, held December 1999)	
	NPL34	NCBI Entrez, Accession No. AF010302, Mandriota S.J. and Pepper, M.S. (first available July 16, 1997)	
	NPL35	NCBI Entrez, Accession No. S08167, Paulsson, G. <i>et al.</i> (first available April 23, 1993)	
	NPL36	NCBI Entrez, Accession No. AAW27553, Han, Z. (first available February 23, 2005)	
	NPL37	Dialog File 351, Accession No. 12299390, WPI English language abstract of WO 98/55619 A1 (Document FP5 listed on accompanying SB/08A)	

Examiner Signature		Date Considered	3/30/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Jing-Shan HU
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
				Attorney Docket Number	1488.1000009/HCC/LMB
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ³ Kind Code ⁴ (if known)				
Bl	FP12	EP 0 186 084 A2	07/02/1986	Merck & Co. Inc.		
	FP13	JP 64-38100 A	02/08/1989	Toray Ind. Inc.		Abs
	FP14	JP 2-117698 A	05/02/1990	Ajinomoto KK and Toray Ind. Inc.		Abs
	FP15	EP 0 399 816 A1	11/28/1990	Merck & Co. Inc.		
	FP16	WO 94/11506 A1	05/26/1994	Arch Development Corporation		
	FP17	WO 00/45835 A1	08/10/2000	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		
	FP18	WO 02/11769 A1	02/14/2002	Human Genome Sciences, Inc. and Coleman		
	FP19	WO 02/083704 A1	10/24/2002	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		

Examiner Signature		Date Considered	3/30/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---


Application Number	09/257,272
Filing Date	February 25, 1999
First Named Inventor	Jing-Shan HU
Art Unit	1647
Examiner Name	Landsman, Robert S.
Attorney Docket Number	1488.1000009/HCC/LMB

[illegible][illegible]

Examiner Signature	<i>Lattse</i>	Date Considered	3/30/06
-----------------------	---------------	--------------------	---------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Jing-Shan HU
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
				Attorney Docket Number	1488.1000009/HCC/LMB
Sheet	1	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
RL	NPL38	Borg, J.-P., <i>et al.</i> , "Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase," <i>Oncogene</i> 10:973-984, Stockton Press (March 1995)	
	NPL39	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-01, Abstract (January 1994)	
	NPL40	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-02, Abstract (January 1995)	
	NPL41	Choi, I.H., <i>et al.</i> , "Angiogenesis and Mineralization During Distraction Osteogenesis," <i>J. Korean Med. Sci.</i> 17:435-447, The Korean Academy of Medical Sciences (August 2002)	
	NPL42	Copy of Declaration of Dr. Kari Alitalo, In re of: U.S. Application No. 08/585,895, Alitalo <i>et al.</i> , filed January 12, 1996, submitted November 26, 1997	
	NPL43	Dias, S., <i>et al.</i> , "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," <i>Blood</i> 99:2179-2184, The American Society of Hematology (March 2002)	
	NPL44	English language abstract of JP 64-38100 A, cited as document FP13 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912	
	NPL45	English language abstract of JP 2-117698 A, cited as document FP14 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024	
	NPL46	Fan, T.-P.D., <i>et al.</i> , "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Trends Pharmacol. Sci.</i> 16:57-66, Elsevier Science Ltd. (February 1995)	
	NPL47	Isner, J.M., <i>et al.</i> , "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," <i>Circulation</i> 91:2687-2692, American Heart Association, Inc. (June 1995)	

Examiner Signature		Date Considered	3/30/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Jing-Shan HU
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	2	of	4	Attorney Docket Number	1488.1000009/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BK	NPL48	Isner, J.M. and Feldman, L.J., "Gene therapy for arterial disease," <i>Lancet</i> 344:1653-1654, The Lancet Ltd. (December 1994)	
	NPL49	Isner, J.M., <i>et al.</i> , "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth Factor," <i>J. Cell. Biochem. (Suppl. 21A)</i> :378, Abstract C6-215, Wiley-Liss (March-April 1995)	
	NPL50	Isner, J.M., "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL53354-01, Abstract (March 1995)	
	NPL51	Kubo, H., <i>et al.</i> , "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblasts growth factor-2-induced lymphangiogenesis in mouse cornea," <i>Proc. Natl. Acad. Sci.</i> 99:8868-8873, The National Academy of Sciences (June 2002)	
	NPL52	Kuzuya, M. and Kinsella, J.L., "Induction of Endothelial Cell Differentiation <i>in Vitro</i> by Fibroblast-Derived Soluble Factors," <i>Exp. Cell Res.</i> 215:310-318, Academic Press, Inc. (December 1994)	
	NPL53	Maher, P.A., "Stimulation of Endothelial Cell Proliferation by Vanadate Is Specific for Microvascular Endothelial Cells," <i>J. Cell. Physiol.</i> 151:549-554, Wiley-Liss, Inc. (1992)	
	NPL54	Mesri, E.A., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice," <i>Circulation Res.</i> 76:161-167, American Heart Association, Inc. (February 1995)	
	NPL55	Mühlhauser, J., <i>et al.</i> , "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," <i>Circulation</i> 88:I-475, Abstract No. 2558, American Heart Association (October 1993)	
	NPL56	Mühlhauser, J., <i>et al.</i> , "VEGF ₁₆₅ Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis <i>In Vivo</i> ," <i>Circulation Res.</i> 77:1077-1086, American Heart Association, Inc (December 1995)	
	NPL57	Oikawa, T., <i>et al.</i> , "Three Isoforms of Platelet-Derived Growth Factors All Have the Capability to Induce Angiogenesis <i>In Vivo</i> ," <i>Biol. Pharm. Bull.</i> 17:1686-1688, (December 1994)	

Examiner Signature		Date Considered	3/30/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Jing-Shan HU
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	3	of	4	Attorney Docket Number	1488.1000009/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
PK	NPL58	Pajusola, K., <i>et al.</i> , "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," <i>Oncogene</i> 9:3545-3555, Stockton Press Ltd. (December 1994)	
	NPL59	Pepper, M.S., <i>et al.</i> , "In Vitro Angiogenic and Proteolytic Properties of Bovine Lymphatic Endothelial Cells," <i>Exp. Cell Res.</i> 210:298-305, Academic Press, Inc. (January 1994)	
	NPL60	Plate, K.H., "From angiogenesis to lymphangiogenesis," <i>Nat. Med.</i> 7:151-152, Nature America, Inc. (February 2001)	
	NPL61	Spranger, J. and Pfeiffer, A.F.H., "New concepts in pathogenesis and treatment of diabetic retinopathy," <i>Exp. Clin. Endocrinol. Diabetes</i> 109(Suppl. 2):S438-S450, J.A. Barth Verlag (2001)	
	NPL62	Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Taylor & Francis (1999)	
	NPL63	Symes, J.F. and Sniderman, A.D., "Angiogenesis: potential therapy for ischaemic disease," <i>Curr. Opin. Lipidol.</i> 5:305-312, Current Science Ltd. (August 1994)	
	NPL64	Takeshita, S., <i>et al.</i> , "In Vivo Evidence of Enhanced Angiogenesis Following Direct Arterial Gene Transfer of the Plasmid Encoding Vascular Endothelial Growth Factor," <i>Circulation</i> 88:I-476, Abstract No. 2565, American Heart Association (October 1993)	
	NPL65	Takeshita, S., <i>et al.</i> , "Therapeutic Angiogenesis. A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," <i>J. Clin. Invest.</i> 93:662-670, The American Society for Clinical Investigation, Inc. (February 1994)	
	NPL66	Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res.</i> 3:147-153, BioMed Central Ltd. (February 2001)	
	NPL67	Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," <i>Am. J. Med. Sci.</i> 306:129-136, Lippincott Williams & Wilkins (August 1993)	

Examiner Signature		Date Considered	3/30/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/257,272
				Filing Date	February 25, 1999
				First Named Inventor	Jing-Shan HU
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	4	of	4	Attorney Docket Number	1488.1000009/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
ph	NPL68	Witzenbichler, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," <i>Am. J. Pathol.</i> 153:381-394, American Society for Investigative Pathology, Inc. (August 1998)	
	NPL69	Yeung, P.K.F., "VEGF-2," <i>Curr. Opin. Invest. Drugs</i> 2:796-800, PharmaPress Ltd. (June 2001)	
	NPL70	Anderson, W.F., "Human gene therapy," <i>Nature</i> 392:25-30, Macmillan Magazines Ltd. (April 1998)	
	NPL71	Maynard, J. and Georgiou, G., "Antibody Engineering," <i>Annu. Rev. Biomed. Eng.</i> 2:339-376, Annual Reviews (August 2000)	
	NPL72	Morea, V., <i>et al.</i> , "Antibody Modeling: Implications for Engineering and Design," <i>Methods</i> 20:267-279, Academic Press (March 2000)	
	NPL73	Litwin, M.S., <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," in <i>Human Cytokines: Their Role in Disease and Therapy</i> , Aggarwal, B.B. and Puri, R.K., eds., Blackwell Science, Boston, Chapter 7, pp 101-129 (January 1995)	
	NPL74	Walsh, C.E., <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>Proc. Soc. Exp. Biol. Med.</i> 204:289-300, Society for Experimental Biology and Medicine (December 1993)	

504549_1.DOC

Examiner Signature		Date Considered	3/30/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.